Advanced search
Publication Cover
International Journal of Neuroscience Volume 122, 2012 - Issue 1
Submit an article Journal homepage
227
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Clinical and Radiological Disease Reactivation After Cessation of Long-Term Therapy With Natalizumab

Annette BaumgartnerDepartment of Neurology, Albert Ludwigs University Freiburg, Freiburg, Germany;Department of Neurology, Albert Ludwigs University Freiburg, Freiburg, GermanyCorrespondence[email protected]
,
Oliver StichDepartment of Neurology, Albert Ludwigs University Freiburg, Freiburg, Germany
&
Sebastian RauerDepartment of Neurology, Albert Ludwigs University Freiburg, Freiburg, Germany
Pages 35-39 | Received 16 Mar 2011, Published online: 11 Jan 2012

REFERENCES

  • Lindå H, Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med. 2009;361:1081–7.
  • Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol. 1994;36:73–9.
  • Miravelle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 Feb;68(2):186–91.
  • Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.
  • O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman CH, Rudick RA, Lynn F, Panzara MA, Sandrock AW for the AFFIRM and SENTINEL investigators. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Mult Scler. 2006;12:S17.
  • Stüve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, Radü EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72:396– 401.
  • Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70:1150–1.
  • Fox RJ, Kappos L. Is natalizumab overshooting its rebound? Neurology. 2008;70:1073–4.
  • Schiess N, Calabresi PA. Natalizumab: bound to rebound? Neurology. 2009;72:392–3
  • Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010 Sep;68(3):392–5.
  • West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010 Sep;68(3): 395–9.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.